Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liquigen is a medical food consisting of a high-energy medium-chain triglyceride (MCT) emulsion (approximately 50% MCT oil and 50% water). It is manufactured by Nutricia and is primarily used for the dietary management of conditions requiring MCTs, such as long-chain fatty acid oxidation disorders (LC-FAODs)—including carnitine palmitoyltransferase II (CPT II) deficiency, long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, mitochondrial trifunctional protein (MTP) deficiency, and very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. It is also used in the management of the ketogenic diet. Liquigen provides an alternative energy substrate that bypasses the defective long-chain fatty acid oxidation pathway. It can be administered orally or enterally and must be used under medical supervision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Liquigen.